Talphera Raises $17 Million in Private Placement Led by CorMedix
Talphera Inc. has announced the closing of the first tranche of a private placement financing, raising $17 million as part of a two-tranche deal for up to $29 million. The financing round was led by CorMedix, Inc. and included participation from existing investors Nantahala Capital, Rosalind Advisors, Rock Springs Capital, as well as new institutional investors. The second tranche is contingent on Talphera's stock price reaching or exceeding $0.6875 for five consecutive days following the achievement of the primary endpoint in the NEPHRO CRRT study, though investors may waive this condition. In addition, certain purchasers have already waived conditions to enable further closings, resulting in additional gross proceeds of approximately $1.6 million.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Talphera Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-25-034446), on November 12, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.